Compare Alcon AG (ALC) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs The Vita Coco Company Inc — how do they compare? Alcon AG trades at $66.7 (market cap $32.69B), while The Vita Coco Company Inc trades at $67.39 (market cap $3.74B). The key difference: Alcon AG is far larger — about 8.7× The Vita Coco Company Inc's market cap, and Alcon AG pays a 0.54% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| ALC | COCO | |
|---|---|---|
Market Cap | $32.69B | $3.74B |
Sector | Health | Technology |
52-Week High | $92.22 | $84.02 |
52-Week Low | $62.02 | $32.30 |
Enterprise Value | $36.28B | $3.56B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
COCO trades at $66.78, up 0.94% today, with a bullish technical signal driven by oversold RSI readings but bearish moving averages. The company reported strong Q1 2026 EPS of $0.50, beating expectations, and shows robust profitability with a 12.59% net margin and 26.32% ROE. Recent news highlights market dominance in coconut water and expanded partnerships, supporting growth prospects amid a $125 billion market opportunity.
Outlook is positive with a consensus price target of $79.33, implying 19% upside, though high valuation multiples (P/E 48.39) and competitive pressures pose risks. Investors should weigh strong earnings momentum against potential volatility from sector rotation and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
